IDYA

SEC source: 0001567619-21-013156 · doc1.xml · nonDerivative · entry 1

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-013155 · doc1.xml · derivative · entry 8

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,610

Underlying: Common Stock · 2,390 shares

Expires 2030-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from July 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-013155 · doc1.xml · derivative · entry 7

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,390

Underlying: Common Stock · 7,610 shares

Expires 2029-10-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from October 9, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 6

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades in prices ranging from $22.57 to $22.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 5

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $21.56 to $22.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 4

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,390

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades in prices ranging from $22.57 to $22.79, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 3

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,532

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $21.56 to $22.56, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 2

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-013155 · doc1.xml · nonDerivative · entry 1

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-012384 · doc1.xml · derivative · entry 6

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,000

Underlying: Common Stock · 3,893 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 4

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,789

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F3 · price: This transaction was executed in multiple trades in prices ranging from $22.45 to $22.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 3

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 102,682

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-012384 · doc1.xml · derivative · entry 5

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,893

Underlying: Common Stock · 1,107 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 2

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,789

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $22.45 to $22.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-012384 · doc1.xml · nonDerivative · entry 1

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,896

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-012208 · doc1.xml · derivative · entry 1

YARNO WENDY L · CIK 0001181186 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-06-09

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

SEC source: 0001567619-21-012207 · doc1.xml · derivative · entry 1

Stein Jeffrey · CIK 0001478831 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-06-09

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

SEC source: 0001567619-21-012206 · doc1.xml · derivative · entry 1

ROSEN TERRY J · CIK 0001182473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-06-09

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

SEC source: 0001567619-21-012238 · doc1.xml · derivative · entry 1

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-06-09

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

SEC source: 0001567619-21-012205 · doc1.xml · derivative · entry 1

Morrison Scott W · CIK 0001662426 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-06-09

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

SEC source: 0001567619-21-012204 · doc1.xml · derivative · entry 1

Hampton Malcolm Garret · CIK 0001698265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2031-06-09

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

SEC source: 0001567619-21-011941 · doc1.xml · derivative · entry 3

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Underlying: Common Stock · 1,500 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-011941 · doc1.xml · nonDerivative · entry 2

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,789

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $19.95 to $20.495, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-011941 · doc1.xml · nonDerivative · entry 1

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-22-008545 · doc1.xml · nonDerivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,803

F1 · shares: Acquired pursuant to Issuer's Employee Stock Purchase Plan.

SEC source: 0001567619-21-009897 · doc1.xml · derivative · entry 3

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 5,000 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-009897 · doc1.xml · nonDerivative · entry 2

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,789

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $19.97 to $20.76, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-009897 · doc1.xml · nonDerivative · entry 1

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-005111 · doc1.xml · derivative · entry 1

Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-005112 · doc1.xml · derivative · entry 1

Hata Yujiro S · CIK 0001649119 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 195,000 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-005115 · doc1.xml · derivative · entry 1

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-005114 · doc1.xml · derivative · entry 1

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-005113 · doc1.xml · derivative · entry 1

Throne Jason · CIK 0001790865 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,500

Underlying: Common Stock · 52,500 shares

Expires 2031-02-23

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-004153 · doc1.xml · derivative · entry 1

Kelley Susan L. · CIK 0001519612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from February 12, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-004152 · doc1.xml · derivative · entry 1

Kelley Susan L. · CIK 0001519612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2031-02-11

F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from February 12, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-002852 · doc1.xml · derivative · entry 10

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,014

Underlying: Common Stock · 596 shares

Expires 2028-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 7

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 6

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 596

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002869 · doc1.xml · derivative · entry 3

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,500

Underlying: Common Stock · 5,000 shares

Expires 2030-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-002869 · doc1.xml · nonDerivative · entry 2

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,789

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $20.41 to $21.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-002869 · doc1.xml · nonDerivative · entry 1

Dillon Michael P. · CIK 0001777415 · SVP, Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,789

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002852 · doc1.xml · derivative · entry 9

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,610

Underlying: Common Stock · 1,104 shares

Expires 2028-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 5

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2 · price: This transaction was executed in multiple trades in prices ranging from $21.00 to $21.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 4

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,104

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001567619-21-002852 · doc1.xml · derivative · entry 8

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,714

Underlying: Common Stock · 300 shares

Expires 2028-12-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from December 11, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 3

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 2

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

SEC source: 0001567619-21-002852 · doc1.xml · nonDerivative · entry 1

Lackner Mark · CIK 0001777413 · SVP, Head of Biology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000921895-21-000223 · form407422010_02042021.xml · nonDerivative · entry 3

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,150

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F4 · ownership.direct: Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

SEC source: 0000921895-21-000223 · form407422010_02042021.xml · nonDerivative · entry 2

BVF PARTNERS L P/IL · CIK 0001055947 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND L P · CIK 0000918923 · See Explanation of Responses

BVF I GP LLC · CIK 0001803805 · See Explanation of Responses

BIOTECHNOLOGY VALUE FUND II LP · CIK 0001102444 · See Explanation of Responses

BVF II GP LLC · CIK 0001803806 · See Explanation of Responses

Biotechnology Value Trading Fund OS LP · CIK 0001660683 · See Explanation of Responses

BVF Partners OS Ltd. · CIK 0001660684 · See Explanation of Responses

BVF GP HOLDINGS LLC · CIK 0001803809 · See Explanation of Responses

BVF INC/IL · CIK 0001056807 · See Explanation of Responses

LAMPERT MARK N · CIK 0001233840 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,188,131

F1 · security: This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Following the transactions reported herein, for the purposes of Section 16, the Reporting Persons ceased to beneficially own 10% or more of the outstanding shares of Common Stock of the Issuer. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.direct: Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.